1. Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients

   • Maria Jose Solana
   • Jesús López-Herce

   Review Article 30 December 2009 Pages: 323 - 330

2. Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact

   • Zoltán Kiss
   • Steven Elliott
   • János Szegedi

   Review Article 02 February 2010 Pages: 331 - 340

   

3. Unbalanced reporting of benefits and harms in abstracts on rofecoxib

   • Anders W. Jørgensen
   • Karsten Juhl Jørgensen
   • Peter C. Gøtzsche

   Special Article 17 February 2010 Pages: 341 - 347

   

4. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients

   • Filip Josephson
   • Maria C. H. Andersson
   • Ylva Böttiger

   Clinical Trial 05 December 2009 Pages: 349 - 357

   

5. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria

   • Antonia C. Kastoris
   • Petros I. Rafailidis
   • Matthew E. Falagas

   Pharmacodynamics 26 February 2010 Pages: 359 - 368

6. Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example

   • Alain Li-Wan-Po
   • Peter Farndon
   • Michael Griffiths

   Pharmacogenetics 29 January 2010 Pages: 369 - 374

   

7. Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting

   • Annette Haberl
   • Manfred Moesch
   • Nils von Hentig

   Pharmacokinetics and Disposition 24 December 2009 Pages: 375 - 381

   

8. CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity

   • Henrik Gréen
   • Karin Skoglund
   • Kourosh Lotfi

   Pharmacokinetics and Disposition 07 January 2010 Pages: 383 - 386

   

9. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone

   • Teijo I. Saari
   • Juha Grönlund
   • Klaus T. Olkkola

   Pharmacokinetics and Disposition 14 January 2010 Pages: 387 - 397

   

10. Prevalence, incidence and persistence of anti-asthma medication use in 2- to 29-year-olds: a nationwide prescription study

    • Øystein Karlstad
    • Per Nafstad
    • Kari Furu

    Pharmacoepidemiology and Prescription 21 November 2009 Pages: 399 - 406

    

11. Do medical students copy the drug treatment choices of their teachers or do they think for themselves?

    • J. Tichelaar
    • M. C. Richir
    • Th. P. G. M. De Vries

    Pharmacoepidemiology and Prescription Open access 24 November 2009 Pages: 407 - 412

12. Drug dependence associated with triptans and ergot derivatives: a case/non-case study

    • Frédérique Beau-Salinas
    • Annie Pierre Jonville-Béra
    • Elisabeth Autret-Leca

    Pharmacoepidemiology and Prescription 19 December 2009 Pages: 413 - 417

13. The effect of long-term danazol prophylaxis on liver function in hereditary angioedema—a longitudinal study

    • Henriette Farkas
    • Ibolya Czaller
    • István Karádi

    Pharmacoepidemiology and Prescription 19 December 2009 Pages: 419 - 426

14. Possible hepatotoxic effect of rooibos tea: a case report

    • Marjatta Sinisalo
    • Anna-Liisa Enkovaara
    • Kari T. Kivistö

    Letter to the Editors 14 January 2010 Pages: 427 - 428